Many investors are wondering why Aurora Cannabis Inc. (NYSE: ACB) stock is down today. Here’s what you need to know.
Checkout this video:
Aurora Cannabis Inc. (ACB) stock fell sharply on Thursday after the company announced it would conduct a strategic review that could lead to a sale of the company.
The Canadian pot producer said it would explore a “variety of options” including joint ventures, partnerships, or a sale of the company, among other things. The strategic review comes as Aurora has been struggling to turn a profit amid fierce competition in the Canadian cannabis market and slowing growth in the global pot industry.
Aurora’s stock plunge added to the selling pressure on pot stocks, which have been under pressure in recent months amid concerns about oversupply in Canada and slowing demand for legal marijuana.
Reasons for the stock decline
Aurora Cannabis Inc. is a publicly traded Canadian company involved in the cultivation, production and sale of medical cannabis. The company’s common shares trade on the Toronto Stock Exchange under the ticker symbol “ACB”, and it also trades on the New York Stock Exchange under the ticker symbol “ACB”. As of October 2018, Aurora Cannabis had a market capitalization of over CAD$7 billion.
In late 2018, Aurora Cannabis’ stock price declined sharply, and as of December 2018, it was down nearly 60% from its 52-week high. There are several reasons for this decline:
-The general decline of the cannabis sector: In late 2018, there was a sharp sell-off in the global cannabis sector. This was due to a combination of factors, including overvaluation, regulatory concerns, and negative publicity around cannabidiol (CBD) products. As one of the largest companies in the sector, Aurora Cannabis was affected by this sell-off.
-Increased competition: The number of companies operating in the legal cannabis industry has increased significantly in recent years, and Aurora Cannabis faces stiff competition from both large and small companies. In particular, Canopy Growth Corporation (Aurora’s main competitor) has been aggressively expanding its business and has partnered with Constellation Brands (a large beverage company) to develop cannabis-infused drinks. Canopy Growth’s expansion plans have put pressure on Aurora Cannabis’ stock price.
-Supply issues: Canada legalized recreational cannabis in October 2018, but there have been issues with supply shortages since then. This has been due to both regulatory delays in approving new cultivators and problems with licensed producers not being able to meet demand. These shortages have led to supply constraints and higher prices for consumers, which could negatively impact sales of legal cannabis products (including those sold by Aurora Cannabis).
-Decelerating growth: In its most recent quarterly report (for the quarter ended September 30, 2018), Aurora Cannabis reported slower revenue growth compared to previous quarters. This deceleration caused some investors to question whether the company can continue to grow at its current pace.
The future of Aurora Cannabis
Aurora Cannabis (NYSE: ACB) is one of the largest cannabis companies in the world, but its stock has been struggling in 2019. Aurora’s shares are down nearly 40% from their 52-week high, and the company is facing a number of challenges that could continue to weigh on its stock in the future.
Aurora’s biggest problem is that it is losing money. The company reported a net loss of C$359 million ($273 million) in its most recent quarter, and its net losses have totaled C$1.2 billion ($914 million) over the last year. Aurora’s losses are largely due to its aggressive expansion strategy, which has included a number of acquisitions. These acquisitions have helped Aurora grow its revenue, but they have also been expensive and have resulted in significant integration costs.
In addition to its financial problems, Aurora is also facing increased regulatory scrutiny in Canada. The Canadian government is expected to implement new regulations that will limit the size of cannabis companies and their ability to advertise their products. These new regulations could be a major headwind for Aurora and other large Canadian cannabis companies.
Finally, Aurora is contending with a competitive landscape that is only getting more crowded. There are now dozens of large cannabis companies operating in Canada, and many of them are well-funded and are expanding rapidly. This increased competition could put pressure on Aurora’s margins and cause it to lose market share in the future.
Given all of these challenges, it’s not surprising that investors have been selling Aurora’s stock this year. And with the company still losing money and facing significant headwinds, there’s a good chance that Aurora’s share price will continue to struggle in the near future.
The potential of the cannabis industry
The potential of the cannabis industry has long been touted as a major reason to invest in Aurora Cannabis (NYSE: ACB). However, the sector has been embroiled in controversy and regulatory uncertainty, which has led to wild swings in stock prices.
Aurora Cannabis is one of the leading producers and sellers of medical and recreational marijuana in Canada. The company has operations in 24 countries and holds a majority stake in CanniMed Therapeutics, one of Canada’s largest licensed producers of medical marijuana.
The company’s shares have been under pressure recently amid concerns about the potential for oversupply in the Canadian market and slowing sales growth. In addition, Aurora Cannabis is facing a number of lawsuits related to its business dealings.
Despite the challenges, Aurora Cannabis remains one of the top picks for growth investors. The company is well-positioned to benefit from the global expansion of the cannabis industry.
The competition in the cannabis industry
In the past year, the cannabis industry has seen a lot of excitement and growth. New companies are entering the market and existing companies are expanding their operations. This increased competition is putting pressure on Aurora Cannabis Inc. (NYSE: ACB), one of the leading producers of cannabis.
The company’s stock has been under pressure in recent months as investors worry about its ability to compete in this rapidly changing market. In this article, we’ll take a look at some of the reasons why Aurora’s stock is down and what the company is doing to try to turn things around.
One of the biggest challenges facing Aurora is the increasing competition in the cannabis industry. There are now dozens of companies producing and selling cannabis products, and many of them are well-funded and eager to gain market share. This competitive pressure has caused prices for Aurora’s products to drop, which has hurt its profitability.
In response to this competitive pressure, Aurora has been trying to cut costs and improve its efficiency. The company has also been working on expanding its product line beyond dried cannabis flower into higher-margin products like edibles and extracts. These initiatives have not been enough to offset the impact of competition, but they may start to pay off in the long run.
Another challenge for Aurora is the slow rollout of legal recreational cannabis in Canada. The Canadian government only recently legalized recreational cannabis, and there have been delays in setting up the regulatory framework for its sale. This has meant that Aurora has not been able to sell recreational cannabis as quickly as it had hoped, which has hurt its growth prospects.
Aurora is taking steps to try to address these challenges, but it remains to be seen whether they will be successful. In the meantime, investors are likely to remain cautious about the stock.
The impact of the coronavirus pandemic
Aurora Cannabis Inc. is a Canadian cannabis company, founded in 2013. The company is based in Edmonton, Alberta, Canada. Aurora Cannabis is one of the world’s largest cannabis companies with sales and operations in 25 countries.
The company sells medical cannabis in Canada and Germany, and recreational cannabis in 9 US states. It has production facilities in Canada, Denmark, Italy, and Portugal.
In March 2020, the coronavirus pandemic caused a decrease in the demand for Aurora Cannabis’ products due to the closure of dispensaries and limits on social gatherings. This decrease in demand caused Aurora Cannabis’ stock price to drop by over 50%.
The challenges facing Aurora Cannabis
Aurora Cannabis (ACB) is one of the leading producers and sellers of medical and recreational marijuana in North America. The company is based in Canada, where it is one of the top licensed producers of cannabis. Aurora also has operations in 24 countries across five continents.
The company’s share price has been under pressure recently, falling by almost 50% from its 52-week high of C$16.24 reached in October 2018. So what’s behind the sell-off? Here are three challenges facing Aurora Cannabis.
1. Slowing industry growth
The legal cannabis industry is still in its early stages and growing rapidly. However, growth is beginning to slow down in North America, the industry’s largest market. In Canada, for example, sales grew by just 5% in the fourth quarter of 2018 compared to the previous quarter. This was the slowest quarter-on-quarter growth rate since Canada legalized recreational cannabis in October 2018.
2. Excess supply
There is too much cannabis being produced and not enough demand to consume it all. This has led to a sharp decline in prices, which is squeezing margins for producers like Aurora Cannabis. In its last reported quarter, the company’s average selling price per gram fell by 17% compared to the previous quarter.
The potential solutions for Aurora Cannabis
Aurora Cannabis Inc (NYSE: ACB) stock is down 16% on Tuesday after the company announced it was suspending production at its Aurora Nordic 2 facility in Denmark. The move comes as Aurora looks to cut costs and improve its profitability.
The company has been under pressure to improve its bottom line, and this move is a step in that direction. However, investors are clearly worried about the long-term prospects for Aurora, and the stock remains under pressure.
Here are three potential solutions for Aurora Cannabis stock.
1. Improve margins with cost cuts
Aurora Cannabis is taking steps to improve its margins by suspending production at its Aurora Nordic 2 facility in Denmark. The company is also looking to cut costs in other areas, such as marketing and admin expenses. If successful, these cost-cutting measures could help Aurora return to profitability.
2. Expand into new markets
Aurora Cannabis has a strong presence in the Canadian cannabis market, but it remains to be seen if the company can replicate this success in other markets. Aurora has made moves into the US CBD market with its acquisition of Gaia Bloom Farms, but this is a small market compared to potential opportunities in Europe and Asia. Expanding into these new markets could provide a much-needed boost to Aurora’s top line.
3. Sell non-core assets
Aurora Cannabis’s acquisition spree has left the company with a number of non-core assets on its balance sheet. Selling off these assets could help improve the company’s financial position and provide some much-needed cash flow relief.
The bottom line
Aurora Cannabis Inc. (NYSE: ACB) stock is down 80% from its 52-week high of $12.53 set in March. The Canadian marijuana producer has been caught up in the industrywide sell-off that has seen most cannabis stocks lose more than two-thirds of their value since early 2019.
There are several reasons for Aurora’s steep decline. The company’s recent financial results have been disappointing, its insiders have been selling stock, and the overall sector has come under pressure as growing concerns about oversupply and slowing demand have weighed on cannabis valuations.
Aurora reported fiscal second-quarter results on Nov. 14 that fell short of analyst expectations on both the top and bottom lines. The company blamed production disruptions at its new Aurora Sun facility in Alberta for the miss, but investors were clearly unimpressed with the results and sent the stock tumbling 13% lower the next day.
Aurora’s insider selling has also been a concern for investors. Chief Financial Officer Glen Ibbott sold 1 million shares in September in a move that raised eyebrows given the company’s weak share price at the time. And in November, longtime Aurora director Michael Singer sold more than 2 million shares, further eroding investor confidence.
The fundamentals of Aurora’s business are also facing some headwinds as industrywide concerns about oversupply and slowing demand have weighed on cannabis valuations. While Aurora is one of the world’s largest marijuana producers, it faces stiff competition from hundreds of other growers both in Canada and internationally. And with demand growth expected to slow in 2020 due to market saturation in Canada and delays in implementing adult-use sales programs in key markets like Germany and Australia, many investors are worried that Aurora (and the sector as a whole) will struggle to achieve sustained profitability going forward.
1. What happened?
2. How bad is it?
3. Will this affect the company’s long-term prospects?
4. How much did the stock drop?
5. How does this compare to other recent events?
6. What does this mean for shareholders?